Biocryst Pharmaceuticals (BCRX) Short-term Investments (2010 - 2026)

Biocryst Pharmaceuticals' Short-term Investments history runs 17 years deep, the most recent figure standing at $66.8 million for Q1 2026.

• Quarterly Short-term Investments fell 64.82% year-over-year to $66.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.8 million (down 64.82% YoY) and the FY2025 annual result came in at $185.0 million, down 14.4% from the prior year.
• Short-term Investments was $66.8 million for Q1 2026 at Biocryst Pharmaceuticals, down from $185.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $278.3 million in Q4 2023 and bottomed at $48.0 million in Q1 2022.
• A 5-year average of $186.0 million and a median of $189.9 million in 2025 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments jumped 3621.76% — and 2026, when it slumped 64.82%.
• Biocryst Pharmaceuticals' Short-term Investments stood at $119.5 million in 2022, then jumped by 132.84% to $278.3 million in 2023, then slipped by 22.35% to $216.1 million in 2024, then retreated by 14.4% to $185.0 million in 2025, then slumped by 63.89% to $66.8 million in 2026.
• Business Quant data shows BCRX's Short-term Investments at $66.8 million in Q1 2026, $185.0 million in Q4 2025, and $128.8 million in Q3 2025.